BeyondSpring Inc (BYSI) - Total Liabilities
Based on the latest financial reports, BeyondSpring Inc (BYSI) has total liabilities worth $49.92 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore BYSI year-over-year net asset growth to track the company's year-over-year net asset growth rate.
BeyondSpring Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how BeyondSpring Inc's total liabilities have evolved over time, based on quarterly financial data. See BYSI cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
BeyondSpring Inc Competitors by Total Liabilities
The table below lists competitors of BeyondSpring Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Batm Advanced Communications Ltd
TA:BVC
|
Israel | ILA47.67 Million |
|
CTCBIO Inc
KQ:060590
|
Korea | ₩77.43 Billion |
|
Done.ai Group AB
ST:TINGS-B
|
USA | Skr2.19 Billion |
|
OptimumBank Holdings, Inc.
NASDAQ:OPHC
|
USA | $966.15 Million |
|
Joinsoon Electronics MFG Co Ltd
TWO:3322
|
Taiwan | NT$2.03 Billion |
|
Minesto AB
ST:MINEST
|
Sweden | Skr22.24 Million |
|
Cybertech Systems And Software Limited
NSE:CYBERTECH
|
India | Rs1.35 Billion |
|
Amplia Therapeutics Ltd
AU:ATX
|
Australia | AU$1.97 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down BeyondSpring Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BYSI market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.93 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BeyondSpring Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BeyondSpring Inc (2014–2025)
The table below shows the annual total liabilities of BeyondSpring Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $49.92 Million | +2.72% |
| 2024-12-31 | $48.60 Million | +0.69% |
| 2023-12-31 | $48.27 Million | -1.95% |
| 2022-12-31 | $49.23 Million | -18.93% |
| 2021-12-31 | $60.73 Million | +140.81% |
| 2020-12-31 | $25.22 Million | +87.85% |
| 2019-12-31 | $13.42 Million | -18.37% |
| 2018-12-31 | $16.45 Million | +243.18% |
| 2017-12-31 | $4.79 Million | +83.67% |
| 2016-12-31 | $2.61 Million | +98.86% |
| 2015-12-31 | $1.31 Million | -87.58% |
| 2014-12-31 | $10.57 Million | -- |
About BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical t… Read more